Beta Finch - S&P 100 - EN

**BETA FINCH PODCAST SCRIPT**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex financial reports into clear, actionable insights. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're diving into Altria Group's Q1 2026 earnings call - and wow, there's a lot to unpack here, including a CEO transition and some fascinating market dynamics in both cigarettes and nicotine pouches.

**ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Absolutely. Now, let's talk numbers first. Altria delivered a solid start to 2026 with adjusted diluted EPS growing 7.3% in Q1. They're maintaining their full-year guidance of $5.56 to $5.72 per share, which represents 2.5% to 5.5% growth.

**ALEX:** That's a strong performance, but what really caught my attention was the underlying story about consumer behavior. Jordan, can you break down what's happening in the cigarette market?

**JORDAN:** Sure thing. So there are two major trends colliding here. First, we're seeing moderation in the e-vapor category - particularly those illicit flavored disposable products that have been stealing cigarette smokers for years. Federal and state enforcement is finally having an impact, and it looks like the category may have hit a saturation point.

**ALEX:** Which is helping cigarette volumes, right? They declined only 4% when adjusted for trade inventory movements, compared to much steeper declines we've seen in recent years.

**JORDAN:** Exactly. But here's the fascinating part - all of this volume improvement is happening in the discount segment, not premium. Consumers are under serious economic pressure. Gas prices spiked, inflation is still biting, and people are trading down to cheaper brands.

**ALEX:** And Altria is capturing that trade-down with their Basic brand. The numbers here are pretty impressive - Basic grew 2.4 share points year-over-year in the discount segment. Meanwhile, Marlboro actually lost 1.4 share points overall but gained in the premium segment specifically.

**JORDAN:** That's the beauty of their portfolio strategy. They're essentially playing both ends of the market. When premium smokers stay loyal, Marlboro captures them. When economic pressure forces people to trade down, Basic is there waiting.

**ALEX:** Now let's talk about the growth story - oral nicotine pouches. This category is absolutely exploding. Jordan, what's happening with their on! brand?

**JORDAN:** The oral nicotine pouch segment now represents 58% of the total oral tobacco category - that's remarkable growth. Altria's on! portfolio shipped nearly 18% more volume, hitting over 46 million cans in Q1. They launched on! PLUS nationwide in March, and it's already in about 100,000 stores.

**ALEX:** What makes on! PLUS special?

**JORDAN:** Two things: it's the first and only product authorized under the FDA's pilot program for nicotine pouches, which should give them a regulatory advantage. And they're marketing it as "the softest pouch on the planet" using their proprietary NICOSILK technology. They're really trying to differentiate on the user experience.

**ALEX:** Speaking of the FDA, there was interesting commentary about the regulatory environment. CEO William Gifford - and by the way, this was his final earnings call - was pushing hard for the FDA to streamline authorizations for e-vapor products.

**JORDAN:** Right, and his logic makes sense. The e-vapor category is still about 70% illicit products. Gifford argued that faster authorizations combined with sustained enforcement could create a compliant marketplace where authorized manufacturers can serve adult consumers with quality products.

**ALEX:** Let's talk about that CEO transition. Gifford is stepping d

This episode includes AI-generated content.

# Beta Finch Podcast Script: Mastercard Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the corporate speak to bring you what really matters from the latest earnings calls. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Mastercard's Q1 2026 results - and folks, there's a lot to unpack here.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And what a quarter this was for Mastercard! The numbers are pretty impressive - net revenue up 12% and net income jumping 15% year-over-year on a currency-neutral basis. EPS came in at $4.60, which included a nice 10-cent boost from share buybacks.

**ALEX:** That's solid growth, but what caught my attention was how they're navigating some pretty significant headwinds. CEO Michael Miebach was pretty upfront about the geopolitical tensions affecting their cross-border business, particularly related to the Middle East conflict. Jordan, what did you make of their approach to this challenge?

**JORDAN:** It's interesting, Alex. They're seeing pressure on cross-border travel metrics - growth slowed from 8% to just 2% in the first four weeks of April. But here's what I found compelling: Miebach talked about how they immediately pivoted to help customers understand shifting spending patterns. Within 24 hours of the conflict escalating, they had a website up for Middle East customers showing where spending was moving.

**ALEX:** That's the kind of agility you want to see from management. And they're not just sitting back - they're actively helping customers adapt. Speaking of adaptation, let's talk about some of the more futuristic stuff they're working on. This whole AI agent commerce thing sounds pretty wild.

**JORDAN:** Oh, the agentic commerce initiative is fascinating! So basically, they're preparing for a world where AI agents can make purchases on your behalf. They've got something called "Mastercard Agent Pay" and they're working with heavy hitters like OpenAI, Google, and Microsoft. What's really smart is they've developed "verifiable intent" - basically a tamper-proof record of what you actually authorized an AI agent to do.

**ALEX:** That sounds like it could be huge down the road, but where are we in terms of actual volume and adoption?

**JORDAN:** Miebach was honest about this - they're still in early stages for volume. But the infrastructure building is critical. They've enabled nearly all Mastercards globally for Agent Pay, and they're setting the standards for how this whole ecosystem will work. It's classic Mastercard - get in early, help build the rails, then benefit as adoption scales.

**ALEX:** And speaking of getting in early, they're making a big bet on stablecoins with their planned BVNK acquisition. Help our listeners understand what this is all about.

**JORDAN:** Sure. So BVNK is basically a platform that helps with the messy parts of digital assets - sending, receiving, converting, and storing stablecoins. Mastercard sees stablecoins as becoming a meaningful part of money movement, especially for B2B payments, cross-border transactions, and "me-to-me" transfers like funding your own wallet.

The revenue model is basis points on volume, and this opens up addressable markets that Mastercard doesn't participate in today. Plus, BVNK has those hard-to-get licenses and regulatory tools that make this space work.

**ALEX:** It sounds like they're positioning themselves for a multi-rail future - not just cards, but also real-time payments and digital assets. Now, let's talk about their bread and butter value-added services. This segment grew 18% - what's driving that?

**JORDAN:** This is where their data moat reall

This episode includes AI-generated content.

# Beta Finch Podcast Script - Eli Lilly Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Eli Lilly's first quarter 2026 results - and wow, what a quarter this was. Jordan, before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And you're absolutely right about this being a wow quarter. Lilly just posted some absolutely staggering numbers. We're talking about 56% revenue growth year-over-year, bringing in what appears to be massive incretin revenues. But what really caught my attention was their guidance raise - they bumped up their full-year revenue expectations by $2 billion to between $82 and $85 billion.

**ALEX:** That's incredible. Let me put that in perspective for our listeners - the midpoint of that guidance represents 28% growth for the full year. For a company of Lilly's size, that's just phenomenal. And the driving force here is clearly their GLP-1 portfolio - Mounjaro and Zepbound combined brought in $12.8 billion in global revenue just in Q1, contributing $6.7 billion of growth compared to last year.

**JORDAN:** What's fascinating is how this growth is playing out globally. We saw really strong international momentum for Mounjaro. In markets like Brazil and Korea, they're claiming around 60% market share. And here's something interesting - they mentioned that generic semaglutide entry in some markets like India actually seems to be stimulating overall market growth rather than hurting Lilly's position.

**ALEX:** That's a great point about the generics. CEO Dave Ricks made a really insightful comment during the Q&A about how this obesity market behaves differently from traditional pharma categories. He said that because so much of the business is out-of-pocket - 75% of ex-US Mounjaro business and a meaningful portion in the US - they see "quite expansionary volume" when they reduce prices. It's almost like the demand curve is more elastic than typical prescription drugs.

**JORDAN:** Exactly. And speaking of new developments, let's talk about Koundeo - their newly approved oral GLP-1. This is huge because it's the first new incretin medicine launched with obesity as the primary indication, not diabetes. They mentioned having over 20,000 patients treated already with about 80% being new to the class entirely.

**ALEX:** The Koundeo launch strategy is really interesting. They're taking a measured approach - they started with digital campaigns, moved to in-person physician promotion, and they're planning full-scale direct-to-consumer TV advertising in Q3. What I found telling was that they already have over 8,000 prescribers, with a third of them never having prescribed an oral GLP-1 before.

**JORDAN:** And the access piece is critical. They've secured commercial access at two of the three largest pharmacy benefit managers, effective mid-May. Plus, the Medicare Bridge program extension through 2027 could be a game-changer - we're talking about $50 monthly copays for seniors. When an analyst asked about Medicare activation, management indicated this will be a gradual build through 2026 and into 2027.

**ALEX:** Let's talk about their pipeline because they were incredibly busy on the R&D front. They announced four acquisitions this quarter - Orna Therapeutics for autoimmune CAR-T therapies, Centessa for sleep disorders, Colonia for cancer treatments, and Ajax for blood cancers. Plus they had positive Phase III data for multiple programs.

**JORDAN:** The retatrutide data particularly caught my eye. This is their triple agonist - GIP, GLP-1, and glucagon. In the TRANSCEND T2D1 trial, patients lost an average of 25 to 37 pounds while also

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you the insights that matter. I'm Alex, and joining me as always is Jordan. Today we're diving into Caterpillar's absolutely explosive Q1 2026 earnings call - and folks, this was a doozy.

But before we dig in, I need to share an important note: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex, and wow - you're right about this being explosive. I've been covering industrial earnings for years and this Caterpillar quarter was genuinely remarkable. Let me just hit you with some numbers right off the bat - revenue jumped 22% to $17.4 billion, adjusted earnings per share shot up 30% to $5.54, and here's the kicker - their backlog grew to a record $63 billion. That's a 79% increase year-over-year.

**ALEX:** Those are staggering numbers, Jordan. But what really caught my attention was the announcement during the call. Caterpillar is essentially doubling down on their data center bet. They're expanding their large reciprocating engine capacity from 2x their 2024 levels to nearly 3x. That's massive.

**JORDAN:** Absolutely massive, Alex. And CEO Joe Creed was pretty candid about what's driving this - it's the AI revolution. He mentioned that since they first announced capacity expansion plans back in January 2024, their large reciprocating engine backlog has grown by more than 3.5x. Customers aren't just ordering for this year - some orders are going well into 2028.

**ALEX:** What I found fascinating was how this isn't just about backup power anymore. Creed mentioned they're seeing increasing demand for prime power applications - basically data centers that want their own dedicated power generation rather than just backup systems. That's a game changer because prime power means much higher service revenue downstream.

**JORDAN:** Exactly, and that service revenue story is crucial. When you sell backup generators, you get the initial sale and some maintenance. But prime power? That's ongoing fuel, parts, service contracts - it's the gift that keeps on giving. Creed even mentioned this was their sixth agreement for at least 1 gigawatt of equipment for prime power applications.

**ALEX:** Let's talk numbers for investors. They raised their full-year guidance to low double-digit growth - that's up from their previous outlook. And they're projecting free cash flow will be higher than last year's $9.5 billion. But there's a cloud here - tariffs.

**JORDAN:** The tariff situation is really interesting, Alex. They absorbed about $600 million in tariff costs in Q1 alone, which was actually better than their $800 million estimate. But for the full year, they're still looking at $2.2 to $2.4 billion in tariff impacts. CFO Andrew Bonfield, who's retiring after this call, was pretty matter-of-fact about it - they're working on mitigation strategies but it's definitely a headwind.

**ALEX:** Speaking of Bonfield, this was his final earnings call after what sounds like an incredible run as CFO. Kyle Epley is taking over, and he seemed well-prepared during his portion of the call. Any concerns about the transition?

**JORDAN:** Not really - Epley has been with the company for over 20 years and worked closely with Bonfield. What I liked was his detailed breakdown of the Q2 outlook. He's expecting continued strong growth across all segments, with Power and Energy leading the charge. He also provided really granular details on tariff impacts by segment, which shows he's got a handle on the complexities.

**ALEX:** The segment performance was pretty interesting too. Construction Industries had a massive 30% sales increase, Resource Industries grew 4%, and Power and Energy was up 22%.

This episode includes AI-generated content.

# Beta Finch Podcast Script: Bristol-Myers Squibb Q1 2026 Earnings

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Bristol-Myers Squibb's first quarter 2026 results, and there's quite a lot to unpack here.

**JORDAN**: Absolutely, Alex. But before we get started, I want to make sure our listeners know that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX**: Thanks for that, Jordan. Now, let's talk Bristol-Myers Squibb - ticker BMY. This pharmaceutical giant just reported Q1 results, and honestly, they seem to be firing on multiple cylinders right now.

**JORDAN**: The numbers tell a solid story, Alex. Total revenue came in at $11.5 billion, up 1% year-over-year. But here's what's really interesting - their growth portfolio, which includes their newer, more innovative drugs, grew 9% to $6.2 billion. That's nearly half their total revenue now coming from these growth assets.

**ALEX**: That's a massive shift for a company that's been dealing with patent cliffs on older drugs. What stood out to you in terms of specific products driving this growth?

**JORDAN**: Several winners here. Reblozyl grew 15%, Breyanzi - their CAR-T cell therapy - jumped 53%, and Camzyos nearly doubled to $314 million. But the elephant in the room is still Eliquis, their blood thinner, which brought in $4.1 billion and grew 13% despite facing generic competition eventually.

**ALEX**: Let's talk about what CEO Chris Boerner emphasized during the call. He really hammered home three strategic priorities: focusing R&D on life-threatening diseases, executing on their growth portfolio, and maintaining disciplined capital allocation. But Jordan, what caught my attention was all the talk about late 2026 being a make-or-break period for several key programs.

**JORDAN**: Yes, this is crucial, Alex. They have what Boerner called an "increasing cadence of pivotal readouts" coming in late 2026. We're talking about Milvexian for atrial fibrillation and stroke prevention, Cobenfy for Alzheimer's psychosis, and some important cancer drug data. These aren't just incremental updates - these could define the company's growth trajectory for years.

**ALEX**: Let's break down a couple of these. Milvexian is their Factor XI inhibitor, essentially trying to create a blood thinner with less bleeding risk than current options. How big could this be?

**JORDAN**: Potentially massive, Alex. They're testing it against Eliquis - their own blockbuster drug - trying to show it's just as effective but causes less bleeding. Think about it: if you can reduce the main side effect that keeps doctors from prescribing blood thinners, you could expand the treatable patient population significantly. Adam Lenkowsky, their Chief Commercialization Officer, called it having "true blockbuster potential."

**ALEX**: And then there's Cobenfy, which they're testing in Alzheimer's psychosis. This seems like a completely different approach to treating psychiatric symptoms in dementia patients.

**JORDAN**: Right, and this addresses a huge unmet need. Current antipsychotics used in elderly dementia patients carry black box warnings and cause serious side effects like movement disorders and cognitive impairment. Cobenfy works on a completely different mechanism - muscarinic receptors instead of dopamine. If it works, it could be the first approved treatment specifically for Alzheimer's psychosis.

**ALEX**: Now, during the Q&A, there were some really interesting exchanges. One analyst asked about their confidence levels in these trials, and Chief Medical Officer Cristian Massacesi gave pretty detailed responses about trial design and patient selection.

**JORDAN**: What struck me was how specific they we

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into some fascinating quarterly results. Today we're unpacking Amphenol's absolutely monster Q1 2026 earnings call - and folks, when I say monster, I mean it. Jordan, before we jump in, I need to share our standard disclaimer with listeners.

This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

Now Jordan, let's talk about these numbers because they're pretty incredible.

**JORDAN:** Alex, I've been covering tech earnings for years, and this Amphenol quarter is genuinely jaw-dropping. They just posted record sales of $7.6 billion - that's up 58% year-over-year and 33% organically. But here's the kicker - their IT datacom segment, which is heavily exposed to AI infrastructure, grew 81% organically. Eighty-one percent!

**ALEX:** That's insane growth. And their guidance for Q2 is equally aggressive - they're projecting $8.1 to $8.2 billion in sales, which would be another 43-45% year-over-year growth. What's driving this AI boom for them specifically?

**JORDAN:** So Amphenol makes connectors and interconnect products - basically the plumbing that connects all the components in data centers. CEO Adam Norwitt made a really interesting point on the call. He said that virtually all of their sequential growth in IT datacom came from AI-related products. These aren't just any connectors - they're high-speed, high-power interconnects that AI systems absolutely depend on.

**ALEX:** And they just made a huge acquisition to strengthen this position, right? The CommScope deal?

**JORDAN:** Exactly. They closed the CommScope acquisition in January for what appears to be around $2.1 billion based on the context. This gives them fiber optic capabilities to complement their copper products. Norwitt was really excited about this on the call - he kept emphasizing that they now have "the industry's broadest range of high-speed copper, power, and fiber optic interconnect products."

**ALEX:** That seems strategic because there's this big debate in the AI world about whether future systems will use copper or fiber optic connections, right?

**JORDAN:** Exactly, and that's where Amphenol's positioning gets really smart. There was a great exchange during the Q&A about co-packaged optics and other next-gen technologies. Norwitt basically said they don't care which technology wins because they play in both spaces now. His quote was memorable: "no matter what, there's going to be more interconnect."

**ALEX:** So they're betting on the overall trend rather than a specific technology. That makes sense. What about their margins? Because with this kind of growth, you'd expect some operational challenges.

**JORDAN:** That's the really impressive part. Despite integrating a major acquisition and growing at breakneck speed, they maintained adjusted operating margins of 27.3%. That's actually up 380 basis points year-over-year. CFO Craig Lampo attributed this to "robust operating leverage" - basically, they're scaling efficiently.

**ALEX:** And this isn't just an AI story, is it? Looking at their other segments, they seem pretty diversified.

**JORDAN:** Right, and this is important for investors to understand. While IT datacom is now 41% of their business, they're still seeing solid growth elsewhere. Defense was up 25% organically, industrial up 16% organically, even automotive grew modestly. Their book-to-bill ratio was 1.24 to 1, and every single end market had a positive book-to-bill.

**ALEX:** That book-to-bill number is telling - it means orders are coming in 24% faster than they can ship products. There was an interesting question about capacity constraints and long-term supply agreements. Wh

This episode includes AI-generated content.

# Beta Finch Podcast Script: Qualcomm Q2 2026 Earnings

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Qualcomm's second quarter 2026 results, and wow, there's a lot to unpack here.

**JORDAN**: Absolutely, Alex. But before we jump in, let me remind our listeners: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX**: Thanks, Jordan. Now, let's talk numbers. Qualcomm delivered $10.6 billion in revenue with non-GAAP earnings per share of $2.65, hitting the high end of their guidance. But the real story here isn't just the headline numbers—it's this massive pivot toward what CEO Cristiano Amon calls "agentic AI" and their diversification strategy.

**JORDAN**: Right, and let's break down those business segments because they tell an interesting story. QCT, their chip business, brought in $9.1 billion, while licensing pulled in $1.4 billion. But here's what caught my attention—automotive hit another record at $1.3 billion, up 38% year-over-year. They're now at a $5 billion annualized run rate and expect to exit fiscal 2026 above $6 billion.

**ALEX**: That automotive growth is impressive, but I want to talk about this elephant in the room—the China handset situation. They're dealing with what they call "memory industry dynamics" that are causing handset OEMs, particularly in China, to be super cautious with their build plans.

**JORDAN**: Exactly. CFO Akash Palkhiwala was pretty candid about this. He said their China Android shipments are "meaningfully below the scale of end consumer handset demand" because OEMs are drawing down channel inventory due to memory supply issues and price increases. But here's the key—they believe Q3 will be the bottom, with sequential growth expected after that.

**ALEX**: So basically, people are still buying phones, but manufacturers aren't ordering as many chips because they're worried about memory costs. It's like a supply chain traffic jam. But what really fascinated me was Amon's vision for where AI is heading. He's talking about this shift from basic AI inference to what he calls "agentic AI"—AI that can orchestrate multi-step tasks and run continuously in the background.

**JORDAN**: And this is where Qualcomm thinks they have a competitive advantage. Amon argued that agent orchestration is predominantly CPU-bound, and he claims Qualcomm has "the world's best performing CPU across smartphones, PCs, auto, and soon the data center." That's a bold claim, but they're backing it up with some interesting product launches.

**ALEX**: Speaking of bold claims, let's talk about their data center ambitions. This was probably the biggest surprise in the call. They announced they're starting shipments to a "leading hyperscaler" in December for a custom silicon engagement. When pressed for details, Amon was pretty tight-lipped but called it a "multi-generation engagement."

**JORDAN**: The timing on that is interesting because it suggests they've been working on this longer than many people realized. Remember, they acquired AlphaWave earlier, which gives them custom ASIC capabilities. But Amon mentioned they've been talking to data center customers for several quarters even before that acquisition.

**ALEX**: One analyst asked a great question about the competitive landscape, especially with ARM now trying to vertically integrate and NVIDIA focusing on inference. Amon's response was fascinating—he basically laid out how the AI market is evolving from training-focused to inference-focused to now this new phase of "agentic" experiences.

**JORDAN**: Right, and his argument is that as AI becomes more about generating demand for tokens rather than just generating the tokens themselves, you need different types of

This episode includes AI-generated content.

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and joining me as always is Jordan. Today we're diving into Microsoft's absolutely explosive Q3 2026 earnings report that just dropped. Jordan, before we get started, I need to remind our listeners that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Thanks Alex, and wow - where do we even begin with these Microsoft numbers? They just reported record results across the board. Revenue hit $82.9 billion, up 18% year-over-year, and earnings per share came in at $4.27. But the real headline here is their AI business - it's now at a $37 billion annual run rate, growing 123% year-over-year!

ALEX: That AI growth rate is just staggering. But let's put this in perspective - Microsoft Cloud overall generated $54 billion in revenue, up 29%. So AI is becoming a massive piece of their puzzle. What really caught my attention was Satya Nadella talking about how we're at the beginning of "one of the most consequential platform shifts" as agents become the dominant workload.

JORDAN: Absolutely, and you can see this playing out in their Copilot numbers. Microsoft 365 Copilot now has over 20 million paid seats - that's 250% growth year-over-year. Even more impressive, they're seeing weekly engagement levels that match Outlook. Think about that - people are using Copilot as much as they use email!

ALEX: That's a great point about user engagement. And they shared some fascinating customer wins - Accenture alone has over 740,000 seats, which is their largest Copilot deal to date. Companies like Bayer, Johnson & Johnson, and Mercedes are all committing to 90,000+ seats. But Jordan, what I found really interesting was this shift in business model that Amy Hood kept emphasizing.

JORDAN: Yes! The transition from traditional per-seat pricing to what they're calling "seats plus consumption." It's happening across their portfolio - from productivity to coding to security. GitHub Copilot actually announced they're moving to usage-based pricing starting June 1st. This is huge because it means as customers use these AI tools more intensively, Microsoft's revenue can scale accordingly.

ALEX: And they're seeing that intensity increase dramatically. Copilot queries per user were up nearly 20% just quarter-over-quarter. Usage of their first-party agents is up 6x year-to-date. Amy Hood mentioned that in customer service, nearly 60% of their customers are already purchasing usage-based credits.

JORDAN: The infrastructure side of this story is equally compelling. They added another gigawatt of capacity this quarter and are on track to double their overall footprint in two years. But here's the kicker - they're still capacity constrained and expect to remain so through at least 2026. That's both a challenge and an opportunity.

ALEX: Speaking of infrastructure, their CapEx guidance is eye-popping. They're expecting over $40 billion in Q4 alone, and for calendar 2026, they're projecting roughly $190 billion in capital expenditures. That includes about $25 billion from higher component pricing. When an analyst asked about investor concerns over CapEx growing faster than revenue, Amy Hood made a compelling case.

JORDAN: Right, she pointed to their $627 billion in remaining performance obligations - that's contracted revenue they still need to deliver. With demand consistently exceeding supply and usage intensity growing, they feel confident about the ROI on these investments. Satya added that they want to be ready when model capabilities hit those exponential moments - like when agent mode in Excel suddenly "started working."

ALEX: Let's talk about the segment performance. Productivity and Business Processes hit $35 billion in revenue, up 17%. Intelligent Cloud was $34.7 bill

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT: Meta Q1 2026 Earnings**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Meta's Q1 2026 earnings call, and wow - there's a lot to unpack here.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

Jordan, Meta just reported some pretty impressive numbers - $56.3 billion in total revenue, up 33% year-over-year. That's a monster quarter!

**JORDAN:** Absolutely, Alex. And that earnings per share of $10.44 really caught my attention, though there's a big asterisk there - they had an $8 billion tax benefit that boosted things significantly. Without that, we're looking at $7.31 per share, which is still solid but gives us a clearer picture of the underlying performance.

**ALEX:** Right, and speaking of underlying performance, the engagement metrics are where things get really interesting. Mark Zuckerberg spent a lot of time talking about their new AI model called "Muse Spark" from their Meta Superintelligence Labs. This seems like their big bet on competing with OpenAI and Google in the AI race.

**JORDAN:** That's the story of this earnings call, Alex. Meta is going all-in on AI, and I mean ALL-IN. They're increasing their capital expenditure guidance to $125-145 billion for 2026 - that's up from their previous range of $120-135 billion. We're talking about massive infrastructure investments here.

**ALEX:** And the results seem to be paying off already. They're seeing double-digit increases in Meta AI sessions per user since launching Muse Spark. But what really stood out to me was how they're using AI to improve their core recommendation systems. On Instagram, they drove a 10% lift in Reels time spent, and on Facebook, total video time increased more than 8% globally - that's the largest quarter-over-quarter gain in four years!

**JORDAN:** Those engagement improvements are crucial because that's what drives ad revenue, which was $55 billion this quarter, up 33%. But here's what's fascinating - they're not just throwing more ads at people. They're using AI to make ads more effective. They mentioned a 6% increase in conversion rates for landing page view ads and over 8 million advertisers now using their AI-powered creative tools.

**ALEX:** The business AI piece is really taking off too. Susan Li mentioned they now have over 10 million weekly conversations between people and business AIs on their messaging platforms - that's up from just 1 million at the start of the year. That's 10x growth in just one quarter!

**JORDAN:** And let's talk about the elephant in the room - that massive increase in contractual commitments. They added $107 billion in contractual commitments this quarter for infrastructure and cloud deals. That's not just spending money; that's locking in capacity for the next several years.

**ALEX:** Which brings us to the cost management side. Meta announced they're planning workforce reductions in May. They're calling it a move toward a "leaner operating model" to help offset these substantial AI investments. It's interesting - they're betting that AI will make their remaining employees more productive.

**JORDAN:** The Ray-Ban smart glasses story continues to be a bright spot too. Daily users tripled year-over-year, and they're expanding beyond just Ray-Ban to other brands. Mark mentioned this is "one of the fastest growing categories of consumer electronics ever." That's a bold claim, but the numbers seem to back it up.

**ALEX:** In the Q&A, there were some really revealing moments. When asked about return on investment for all this AI spending, Zuckerberg essentially said they're following their traditional playbook: build experiences

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn quarterly reports into conversations you'll actually want to hear. I'm Alex, and I'm joined by my co-host Jordan. Today we're diving into KLA Corporation's Q3 2026 results - and wow, what a quarter this was.

Before we jump in, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And speaking of wow - KLA absolutely crushed it this quarter. Revenue hit $3.415 billion, which was not only up 4% sequentially but also 11% year-over-year. That beat their internal forecasts too.

**ALEX:** Right, and the earnings per share story is even better - $9.40 non-GAAP EPS. But Jordan, what really caught my attention was their forward-looking commentary. They're basically saying 2027 is going to be massive for the semiconductor equipment industry.

**JORDAN:** Exactly. CEO Rick Wallace made some pretty bold statements about visibility into 2027. He said there's "unprecedented demand visibility" from customers and that normally they wouldn't comment on 2027 growth rates in April of 2026, but the demand environment is giving them that confidence. They expect 2027 year-over-year growth to be higher than 2026.

**ALEX:** Let's break down what's driving this optimism. KLA is the leader in process control equipment - think of them as the quality control experts for semiconductor manufacturing. Every time chip makers need to inspect their wafers or measure critical dimensions, they're likely using KLA tools.

**JORDAN:** And AI is clearly the rocket fuel here. The company specifically called out AI as "a core driver of KLA's performance." They're seeing increased investment in leading-edge foundry logic and high bandwidth memory - both critical for AI applications. What's fascinating is they raised their advanced packaging revenue outlook from $635 million to approximately $1 billion for 2026.

**ALEX:** That's a 57% increase! Advanced packaging is becoming crucial as chip companies try to pack more performance into smaller spaces. It's like upgrading from a studio apartment to a high-rise - you need much more sophisticated tools to make sure everything fits perfectly.

**JORDAN:** The numbers tell a compelling story about market share too. KLA increased their global share in both overall wafer equipment and process control markets in 2025. In advanced packaging specifically, they gained 14 percentage points of market share and saw 70% year-over-year revenue growth.

**ALEX:** Now let's talk about the elephant in the room - supply chain constraints. During the Q&A, management acknowledged they're dealing with unprecedented demand urgency from customers. CFO Brent Higgins said customers are showing "a higher level of urgency around securing capacity" than he's seen before.

**JORDAN:** This creates an interesting dynamic. On one hand, it's validation of incredibly strong demand. On the other hand, it means KLA has to rapidly scale operations, hire more people, and ensure they can deliver. The good news is they seem confident about supporting the 2027 ramp.

**ALEX:** Speaking of 2027, let's dig into their industry outlook. They're expecting the wafer equipment market to exceed $140 billion in 2026 - that's up from previous estimates of $135-140 billion. But here's the kicker: they think their semiconductor process control systems business will grow over 20% in 2026, significantly outpacing the broader market.

**JORDAN:** The geographic and end-market mix is interesting too. For the June quarter, they're forecasting foundry logic to be about 82% of revenue with memory at 18%. Within memory, DRAM is expected to be 84% and NAND 16%. This heavy foundry weighting reflects t

This episode includes AI-generated content.